Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01719653 · ClinicalTrials.gov registry record · Phase 4
A Comparison of 5 Low Volume Bowel Preparations
A Phase 4 study, sponsored by Gastroenterology Services.
- Completed
- Registry status
- Phase 4
- Development phase
- 1,079
- Enrollment target
NCT01719653: Completed Phase 4 study, sponsored by Gastroenterology Services.
NCT01719653 is a Phase 4 study that has completed, run by Gastroenterology Services. The registered enrollment target is 1,079 participants, above the 518-participant average among 9,235 other Phase 4 trials with a reported enrollment target (108% higher). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01719653, a Phase 4 study, has completed, sponsored by Gastroenterology Services.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 1,079 participants
- Enrollment target
Study Summary
The purpose of this investigation is to compare 3 versions of MiraLAX/Gatorade, MoviPrep and SUPREP to see which preparation cleanses the colon best and which preparation is best tolerated.
Primary Outcome
The quality of the colon preparation as graded using our new Chicago Bowel Preparation Scale (BPS) (Adventist Midwest Region Institutional Review Board, AMH 2010-01-80; ClinicalTrials.gov NCT01063049). Chicago BPS total score is ranges from 0 (very poor) to 36 (outstanding). Modified Chicago BPS total score is ranges from 0 (very poor) to 33 (outstanding). Chicago BPS Fluid score is ranges from 0 (dry) to 3 (wet).
Interventions
- DRUG MoviPrep
- OTHER Gatorade
- DRUG MiraLAX
- DRUG SUPREP
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1,079 participants |
| Start Date | 2012-10 |
| Est. Completion | 2014-09 |
| Phase | Phase 4 |
What the finished NCT01719653 record still lists
NCT01719653 is an interventional study that assigns participants to a tested intervention. Its 1,079 participants enrollment target places it among the larger protocols in the corpus, above the 518-participant average among 9,235 other Phase 4 trials with a reported enrollment target (108% higher).
The record links to 0 conditions, and to 4 interventions - of which MoviPrep is the first listed.
NCT01719653 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT01719653 about?
NCT01719653 is a clinical study titled "A Comparison of 5 Low Volume Bowel Preparations". The purpose of this investigation is to compare 3 versions of MiraLAX/Gatorade, MoviPrep and SUPREP to see which preparation cleanses the colon best and which preparation is best tolerated.
What is the current status of trial NCT01719653?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 1,079 participants. The study started on 2012-10. Estimated completion is 2014-09.
What interventions are being tested in trial NCT01719653?
The interventions under investigation include: MoviPrep (DRUG), Gatorade (OTHER), MiraLAX (DRUG), SUPREP (DRUG).
Who is sponsoring clinical trial NCT01719653?
This trial is sponsored by Gastroenterology Services, which has 4 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT01719653's enrollment target sits among peer trials
1,079 66th of 2000 higher than 1,935 of 2,000 other Phase 4 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 4 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT06074068 · 1,080 participants · NA
Father-Focused Intervention for Reducing Family Violence and Symptoms in Children
- NCT07213804 · 1,080 participants · Phase 3
A Two-Part Phase 3 Study of Sofetabart Mipitecan (LY4170156) in Participants With Platinum-Resistant (Part A) and Platinum-Sensitive (Part B) Ovarian Cancer
- NCT07084883 · 1,076 participants
Pivotal Trial of an Automated AI-based System for Early Diagnosis and Prediction of Late Age-related Macular Degeneration
- NCT06658808 · 1,075 participants · NA
Efficacy-Implementation Study for PC CARES in Rural Alaska
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia